When a fever strikes in a developing area, the immediate concern may be: Is it the common flu or something much worse that requires quarantine? To facilitate diagnosis in remote, low-resource settings, researchers have developed a paper-based device that changes color, depending on whether the patient has Ebola, yellow fever or dengue. The test takes minutes and does not need electricity to work.
A paper-based diagnostic test distinguishes between yellow fever virus, Ebola and dengue with different colored nanoparticles tagged with antibodies targeting a certain virus. Credit: Chunwan Yen
The team will describe their approach in one of more than 9,000 presentations at the 250th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society, taking place here through Thursday. A brand-new video on the research is available at http://bit.ly/acsebolatest.
Standard approaches for diagnosing viral infections require technical expertise and expensive equipment, Kimberly Hamad-Schifferli, Ph.D., says. "Typically people perform PCR and ELISA, which are highly accurate, but they need a controlled lab environment." Polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) are bioassays that detect pathogens directly or indirectly, respectively.
Color-changing paper devices that work similarly to over-the-counter pregnancy tests offer a possible solution. "These are not meant to replace PCR and ELISA because we can't match their accuracy," Hamad-Schifferli says. "But this is a complementary technique for places with no running water or electricity."
Hamad-Schifferli and her team at the Massachusetts Institute of Technology, Harvard Medical School and the U.S. Food and Drug Administration build silver nanoparticles in a rainbow of colors. The sizes of the nanoparticles determine their colors. Therefore, the team uses different sizes of these chemical ingredients for various hues. The researchers attached red, green or orange nanoparticles to antibodies that specifically bind to proteins from the organisms that cause Ebola, dengue or yellow fever, respectively. They introduced the antibody-tagged nanoparticles onto the end of a small strip of paper. In the paper's middle, the researchers affixed "capture" antibodies to three test lines at different locations, one for each disease. "The strip looks so simple, but it's incredibly complicated," Hamad-Schifferli says. "Putting it all together in an integrated system was really challenging."
To test the device, the researchers spiked blood samples with the viral proteins and then dropped small volumes onto the end of the paper device. If a sample contained dengue proteins, for example, then the dengue antibody, which was attached to a green nanoparticle, latched onto one of those proteins. This complex then migrated through the paper, until reaching the dengue fever test line, where a second dengue-specific antibody captured it. That stopped the complex from going farther down the strip, and the test line turned green. When the researchers tested samples with proteins from Ebola or yellow fever, the antibody complexes migrated to different places on the strip and turned red or orange.
"Using other laboratory tests, we know the typical concentrations of yellow fever or dengue virus in patient blood. We know that the paper-based test is sensitive enough to detect concentrations well below that range," says Hamad-Schifferli. "It's hard to get that information for Ebola, but we can detect down to tens of nanograms per milliliter -- that's pretty sensitive and might work with patient samples."
Next, the researchers plan to produce kits for free distribution. "We're giving people the components so they can build the devices themselves," says Hamad-Schifferli. The kits will provide a flexible platform for making paper devices that can detect any disease of interest, given the right antibody. "We are trying to move this into the field and put it in the hands of the people who need it," she says.